EMA PRAC Meeting Highlights — 9–12 February 2026

18th February 2026

Summary: At its 9–12 February 2026 meeting, PRAC completed a safety review of levamisole-containing medicines (used to treat parasitic worm infections) and recommended withdrawal of their marketing authorisations across the EU. The Committee concluded that cases of leukoencephalopathy — a rare, serious brain white-matter condition that may occur even after a single dose — outweigh any clinical benefit for these products and that no effective risk-mitigation measures exist. In support of this action, PRAC endorsed a direct healthcare professional communication (DHPC) to ensure clinicians are informed about the risks and the withdrawal decision, with dissemination planned via national registers and professional channels.

Link: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-february-2026

Back to Recent News